Alcidion Group Limited · ASX:ALC
Alcidion — Shareholder Meeting (November 2023)
14 slides from Alcidion's shareholder meeting presentation, Nov 20, 2023
Slide 1: FY23 AGM Managing Director's Presentation
For personal use only FY23 AGM MANAGING DIRECTOR’S PRESENTATION 20 November 2023
Slide 2: Challenges facing healthcare providers
Challenges facing healthcare providers For personal use only Healthcare providers must adopt technology to improve patient outcomes and deliver efficiencies to meet demand Healthcare needs to further extend digital capabilities to increase automation and reduce administrative burden Demographic Indu
Slide 3: Investment Highlights
Investment Highlights For personal use only • Large Addressable Market Strong Financial Profile Marquee Customers • 146 Acute UK NHS Trusts; ALC with foothold • ~70% recurring revenue, supported by • $31.7M over 5.5 years with Leidos (Aus) to in only approximately 27% multi-year contracts assist Aus
Slide 4: Customer Success
For personal use only Customer Success
Slide 5: Successful Deployments
Successful Deployments For personal use only Product Implementation and technical services have always been a strength of the Alcidion business Alfred Hospital: Leidos Australia (ADF): • Successful go live across three campuses early • Continued successful, staged delivery of the 2023 using Miya Pre
Slide 6: Where we drive value
Where we drive value Customer reported benefit examples For personal use only Emergency Physician 28.6% Department length reported time 20 mins of stay reduction released per hour Reduction in Nurse handover 42% perceived reduction per shift 90 mins medical errors releasing time to care Reduction in
Slide 7: Case Study: Smartpage, helping reduce medical errors
Case Study: Smartpage, helping reduce medical errors For personal use only Smartpage is an advanced smartphone and web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users. Encrypted messaging supports the 2022 junior doctor
Slide 8: FY23 Financials
For personal use only FY23 Financials
Slide 9: FY23 – Financial Highlights
FY23 – Financial Highlights For personal use only Continuing to build scale through increased recurring revenue supported by positive operating cashflow Revenue $40.4M 18%1 Recurring Revenue $28.1M 21% Gross Margin 86.1% 0.3pts Operating Cashflow $0.2M $0.8M EBITDA ($1.5M) $0.1M FY23 TCV3 new sales
Slide 10: Revenue Dashboard
Revenue Dashboard For personal use only Half-on- half revenue Geographical Split (FY23) (UK / ANZ) UK ANZ Recurring / non- recurring revenue 10
Slide 11: Looking Forward FY24
For personal use only Looking Forward FY24
Slide 12: Continued momentum
Continued momentum For personal use only Key Drivers › $35.3M of contracted and scheduled renewal revenue for FY24 (as of 30 September 2023, before any new sales) › Deep engagement with new and existing customers relating to further module sales against a backdrop of increasing referenceability › Mu
Slide 13: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidio
Slide 14: For personal use only
For personal use only 14